Invasive Candida Infection after Upper Gastrointestinal Tract Surgery for Gastric Cancer
Table 2
Demographic data, postoperative infectious complications, and clinical outcomes endpoints of Group 2 patients divided into nonfungal and invasive fungal subgroups (, %, mean ± SD).
Nonfungal ()
Invasive ()
valu
Age, years (mean ± SD)
72.25 ± 14.29
72.9 ± 14.9
0.15
Weight, Kg (mean ± SD)
72.9 ± 12.9
72.6 ± 13.57
0.9
Gender (male)
21/39 (53.8%)
3/10 (30%)
0.4
Type of upper surgery
Total gastrectomy
22/39 (56.4)
4/10 (40%)
0.61
Partial gastrectomy
17/39 (43.6%)
6/10 (60%)
0.5
Underlying condition (%)
Without chronic disease
10/39 (25.6%)
5/10 (50%)
0.08
Diabetes mellitus
16/39 (41%)
3/10 (30%)
0.08
12/39 (30.7%)
2/10 (20%)
0.16
Hypertension
1/39 (2.5%)
0
NA
Chronic therapy (%)
Without chronic therapy
10/39 (25.6%)
5/10 (50%)
0.04
Statins
13/39 (33.3%)
3/10 (30%)
0.48
16/39 (41%)
2/10 (20%)
0.03
Postoperative complications
Intraperitoneal leak (, %) (documented)
27/39 (69.2%)
9/10 (90%)
0.01
Leak location (n, %)
Gastroesophageal junction
8/39 (34.8%)
8/10 (80%)
0.02
Gastrointestinal anastomosis
7/39 (30.4%)
1/10 (10%)
0.01
Duodenum/small bowel
8/39 (34.8%)
1/10 (10%)
0.02
Intra-abdominal abscesses (, %)
16/39 (41%)
9/10 (90%)
0.006
Presence of pleural effusion (, %)
4/39 (10.3%)
4/10 (40%)
0.04
Clinical outcome endpoints
APACHE (units, mean ± SD)
24.51 ± 6.06
24.2 ± 5.37
0.67
TISS score (units, mean ± SD)
22.48 ± 6.03
22.2 ± 5.37
0.72
ICU length of stay (day, mean ± SD)
11.6 ± 1.5
13.9 ± 1.4
0.65
Hospital length of stay (day, mean ± SD)
34.84 ± 2.6
25.2 ± 1.5
0.11
ICU mortality (%)
6/39 (15.4%)
5/10 (50%)
0.03
was found to be statistically significant. Invasive fungal (Candida) complications: Candida peritonitis, candidemia, and Candida empyema. Gastrointestinal tract; CIHD: chronic ischemic heart disease; ACE: angiotensin-converting enzyme. Within 24 hours of ICU admission.
